par Sangro, Bruno;Martínez-Urbistondo, Diego;Bester, Lourens;Bilbao, Josè Ignacio;Coldwell, Douglas D.M.;Flamen, Patrick 
;Kennedy, Andrew;Ricke, Jens;Sharma, Ricky R.A.
Référence Hepatology, 66, 3, page (969-982)
Publication Publié, 2017-09
;Kennedy, Andrew;Ricke, Jens;Sharma, Ricky R.A.Référence Hepatology, 66, 3, page (969-982)
Publication Publié, 2017-09
Article révisé par les pairs
| Résumé : | Selective internal radiation therapy (or radioembolization) by intra-arterial injection of radioactive yttrium-90-loaded microspheres is increasingly used for the treatment of patients with liver metastases or primary liver cancer. The high-dose beta-radiation penetrates an average of only 2.5 mm from the source, thus limiting its effects to the site of delivery. However, the off-target diversion of yttrium-90 microspheres to tissues other than the tumor may lead to complications. The most prominent of these complications include radiation gastritis and gastrointestinal ulcers, cholecystitis, radiation pneumonitis, and radioembolization-induced liver disease, which may occur despite careful pretreatment planning. Thus, selective internal radiation therapy demands an expert multidisciplinary team approach in order to provide comprehensive care for patients. This review provides recommendations to multidisciplinary teams on the optimal medical processes in order to ensure the safe delivery of selective internal radiation therapy. Based on the best available published evidence and expert opinion, we recommend the most appropriate strategies for the prevention, early diagnosis, and management of potential radiation injury to the liver and to other organs. (Hepatology 2017;66:969–982). |
